Overview

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

Status:
Completed
Trial end date:
2020-01-20
Target enrollment:
Participant gender:
Summary
This study is designed as a combination of phase 1 (Part A) and phase 2 (Part B). The purpose of Part A was to determine the safety, tolerability, and pharmacokinetics in patients with total thyroidectomy or near total thyroidectomy of GX-30 and it has been completed. The Part B is currently recruiting and will investigate the efficacy and safety of GX-30 compared with THYROGEN®.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genexine, Inc.
Collaborator:
Symyoo